De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Noxopharm Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Noxopharm's earnings have been declining at an average annual rate of -9.5%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been declining at an average rate of 4.3% per year.
Belangrijke informatie
-9.5%
Groei van de winst
14.2%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 9.6% |
| Inkomstengroei | -4.3% |
| Rendement op eigen vermogen | -65.1% |
| Nettomarge | -149.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Noxopharm geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -4 | 4 | 0 |
| 31 Mar 24 | 3 | -8 | 4 | 0 |
| 31 Dec 23 | 4 | -12 | 5 | 0 |
| 30 Sep 23 | 5 | -14 | 5 | 0 |
| 30 Jun 23 | 6 | -15 | 6 | 0 |
| 31 Mar 23 | 6 | -15 | 6 | 0 |
| 31 Dec 22 | 7 | -15 | 7 | 0 |
| 30 Sep 22 | 6 | -17 | 7 | 0 |
| 30 Jun 22 | 5 | -19 | 7 | 0 |
| 31 Mar 22 | 6 | -15 | 7 | 0 |
| 31 Dec 21 | 6 | -11 | 6 | 0 |
| 30 Sep 21 | 6 | -10 | 7 | 0 |
| 30 Jun 21 | 6 | -9 | 7 | 0 |
| 31 Mar 21 | 6 | -5 | 7 | 0 |
| 31 Dec 20 | 6 | 0 | 7 | 0 |
| 30 Sep 20 | 7 | 0 | 8 | 0 |
| 30 Jun 20 | 8 | 0 | 8 | 0 |
| 31 Mar 20 | 6 | -7 | 9 | 2 |
| 31 Dec 19 | 4 | -15 | 10 | 4 |
| 30 Sep 19 | 4 | -13 | 10 | 5 |
| 30 Jun 19 | 4 | -11 | 9 | 7 |
| 31 Mar 19 | 4 | -11 | 9 | 6 |
| 31 Dec 18 | 3 | -10 | 8 | 5 |
| 30 Sep 18 | 2 | -14 | 7 | 4 |
| 30 Jun 18 | 1 | -18 | 6 | 4 |
| 31 Mar 18 | 1 | -16 | 5 | 3 |
| 31 Dec 17 | 1 | -14 | 4 | 3 |
| 30 Sep 17 | 1 | -8 | 3 | 2 |
| 30 Jun 17 | 0 | -3 | 2 | 1 |
| 31 Mar 17 | 0 | -3 | 2 | 1 |
Kwaliteitswinsten: NOX is currently unprofitable.
Groeiende winstmarge: NOX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NOX is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.
Versnelling van de groei: Unable to compare NOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: NOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Rendement op eigen vermogen
Hoge ROE: NOX has a negative Return on Equity (-65.11%), as it is currently unprofitable.